Post-COVID-19 syndrome and diabetes mellitus

• Verfasst von: Abumayyaleh, Mohammad S. A. [VerfasserIn]
• Verfasst von: Núñez Gil, Iván J. [VerfasserIn]
• Verfasst von: Viana-LLamas, María C. [VerfasserIn]
• Verfasst von: Raposeiras Roubin, Sergio [VerfasserIn]
• Verfasst von: Romero, Rodolfo [VerfasserIn]
• Verfasst von: Alfonso-Rodríguez, Emilio [VerfasserIn]
• Verfasst von: Uribarri, Aitor [VerfasserIn]
• Verfasst von: Feltes, Gisela [VerfasserIn]
• Verfasst von: Becerra-Muñoz, Víctor Manuel [VerfasserIn]
• Verfasst von: Santoro, Francesco [VerfasserIn]
• Verfasst von: Pepe, Martino [VerfasserIn]
• Verfasst von: Castro Mejía, Alex Fernando [VerfasserIn]
• Verfasst von: Signes-Costa, Jaime [VerfasserIn]
• Verfasst von: Gonzalez, Adelina [VerfasserIn]
• Verfasst von: Marín, Francisco [VerfasserIn]
• Verfasst von: López-País, Javier [VerfasserIn]
• Verfasst von: Manzone, Edoardo [VerfasserIn]
• Verfasst von: Vazquez Cancela, Olalla [VerfasserIn]
• Verfasst von: Paeres, Carolina Espejo [VerfasserIn]
• Verfasst von: Masjuan, Alvaro López [VerfasserIn]
• Verfasst von: Velicki, Lazar [VerfasserIn]
• Verfasst von: Weiß, Christel [VerfasserIn]
• Verfasst von: Chipayo, David [VerfasserIn]
• Verfasst von: Fernandez-Ortiz, Antonio [VerfasserIn]
• Verfasst von: El-Battrawy, Ibrahim [VerfasserIn]
• Verfasst von: Akın, Ibrahim [VerfasserIn]
• Titel: Post-COVID-19 syndrome and diabetes mellitus
• Titelzusatz: a propensity-matched analysis of the International HOPE-II COVID-19 registry
• Verf.angabe: Mohammad Abumayyaleh, Iván J. Núñez Gil, María C. Viana-LLamas, Sergio Raposeiras Roubin, Rodolfo Romero, Emilio Alfonso-Rodríguez, Aitor Uribarri, Gisela Feltes, Víctor Manuel Becerra-Muñoz, Francesco Santoro, Martino Pepe, Alex Fernando Castro Mejía, Jaime Signes-Costa, Adelina Gonzalez, Francisco Marín, Javier López-País, Edoardo Manzone, Olalla Vazquez Cancela, Carolina Espejo Paeres, Alvaro López Masjuan, Lazar Velicki, Christel Weiß, David Chipayo, Antonio Fernandez-Ortiz, Ibrahim El-Battrawy, Ibrahim Akin and HOPE COVID-19 investigators
• E-Jahr: 2023
• Jahr: 16 May 2023
• Umfang: 12 S.
• Fussnoten: Gesehen am 10.07.2023
• Titel Quelle: Enthalten in: Frontiers in endocrinology
• Ort Quelle: Lausanne : Frontiers Research Foundation, 2010
• Jahr Quelle: 2023
• Band/Heft Quelle: 14(2023) vom: Mai, Artikel-ID 1167087, Seite 1-12
• ISSN Quelle: 1664-2392
• DOI: doi:10.3389/fendo.2023.1167087
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1852264292
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext

Abstract

BackgroundDiabetes mellitus (DM) is one of the most frequent comorbidities in patients suffering from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with a higher rate of severe course of coronavirus disease (COVID-19). However, data about post-COVID-19 syndrome (PCS) in patients with DM are limited.MethodsThis multicenter, propensity score-matched study compared long-term follow-up data about cardiovascular, neuropsychiatric, respiratory, gastrointestinal, and other symptoms in 8,719 patients with DM to those without DM. The 1:1 propensity score matching (PSM) according to age and sex resulted in 1,548 matched pairs.ResultsDiabetics and nondiabetics had a mean age of 72.6 ± 12.7 years old. At follow-up, cardiovascular symptoms such as dyspnea and increased resting heart rate occurred less in patients with DM (13.2% vs. 16.4%; p = 0.01) than those without DM (2.8% vs. 5.6%; p = 0.05), respectively. The incidence of newly diagnosed arterial hypertension was slightly lower in DM patients as compared to non-DM patients (0.5% vs. 1.6%; p = 0.18). Abnormal spirometry was observed more in patients with DM than those without DM (18.8% vs. 13; p = 0.24). Paranoia was diagnosed more frequently in patients with DM than in non-DM patients at follow-up time (4% vs. 1.2%; p = 0.009). The incidence of newly diagnosed renal insufficiency was higher in patients suffering from DM as compared to patients without DM (4.8% vs. 2.6%; p = 0.09). The rate of readmission was comparable in patients with and without DM (19.7% vs. 18.3%; p = 0.61). The reinfection rate with COVID-19 was comparable in both groups (2.9% in diabetics vs. 2.3% in nondiabetics; p = 0.55). Long-term mortality was higher in DM patients than in non-DM patients (33.9% vs. 29.1%; p = 0.005).ConclusionsThe mortality rate was higher in patients with DM type II as compared to those without DM. Readmission and reinfection rates with COVID-19 were comparable in both groups. The incidence of cardiovascular symptoms was higher in patients without DM.